Apogee Therapeutics, Inc.
APGE
Rank in Stocks
#2352
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Share Price
$135.07
Last synced: 2026-09-04
Market Cap
$8.36B
Change (1 day)
0.00%
Change (1 year)
137.21%
Country
US
Trade Apogee Therapeutics, Inc. (APGE)
Category
Healthcare
Earnings for Apogee Therapeutics, Inc. (APGE)
Earnings in Jun 2026 TTM: $-294.09M
According to Apogee Therapeutics, Inc. latest financial reports the company's current earnings are $-294.09M. In 2023 the company made an earning of $-83.99M, a decrease compared to its 2022 earnings that were of $-39.79M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Apogee Therapeutics, Inc. from 2022 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-294.09M | 61.48% |
| 2024 | $-182.13M | 116.86% |
| 2023 | $-83.99M | 111.10% |
| 2022 | $-39.79M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,893.62% |
US
|
|
| $-3.09B | 949.67% |
US
|
|
| $-4.02B | 1,265.62% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -763.28% |
NL
|
